Free Trial
NASDAQ:EVGN

Evogene Q2 2025 Earnings Report

Evogene logo
$1.16 -0.04 (-3.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.16 0.00 (-0.09%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evogene EPS Results

Actual EPS
N/A
Consensus EPS
-$0.63
Beat/Miss
N/A
One Year Ago EPS
N/A

Evogene Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.93 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evogene Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 19, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

Evogene Earnings Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
See More Evogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evogene and other key companies, straight to your email.

About Evogene

Evogene (NASDAQ:EVGN), together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

View Evogene Profile

More Earnings Resources from MarketBeat